ABSTRACT
Objective TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration with TDP-43 (FTLD-TDP), and limbic-predominant age-related TDP-43 encephalopathy, encompass a spectrum of clinical and neuropathological traits. Despite mounting evidence for shared genetic risk across TDP-43 proteinopathies, the modifiers of individual-level traits are unknown. We aimed to identify polygenic contributions to trait heterogeneity across TDP-43 proteinopathies.
Methods We used weighted correlation analysis of GWAS summary statistics for ALS, FTLD-TDP, and hippocampal sclerosis of aging (HS-Aging) to identify data-driven modules of highly correlated single nucleotide polymorphisms (SNPs). We performed gene ontology enrichment analysis for each identified module. We derived module-specific polygenic scores and evaluated their association with clinical and neuropathological traits in an independently evaluated sample of individuals who met neuropathological and/or genetic criteria for FTLD-TDP or ALS (n=260).
Results We identified 5 distinct data-driven modules, including 3 GWAS phenotype-specific modules (FTLD-TDP, ALS, HS-Aging) and 2 modules representing the overlap between a pair of GWAS phenotypes (ALS-FTLD and FTLD-HS). Pathway analysis revealed biologically meaningful associations including distinct GWAS phenotype-specific processes within modules. Module-specific ALS and FTLD-TDP polygenic risk each associated with individual-level clinical traits, even within the context of autosomal dominant mutation carriers, where higher ALS polygenic risk associated with neuromuscular impairment and higher FTLD-TDP polygenic risk associated with cognitive-behavioral impairment. Moreover, higher FTLD-TDP polygenic risk associated with higher TDP-43 burden within characteristic FTLD-TDP brain regions. Interpretation: We suggest that there are polygenic modifiers of clinical and neuropathological traits across TDP-43 proteinopathies that may contribute to individual-level differences, including likelihood for developing FTLD or ALS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institutes of Health grant F32AG079618 (BES), P01AG066597 (CTM), NS109260 (DJI), Penn Institute on Aging, and The DeCrane Family Fund for Primary Progressive Aphasia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All summary statistic data was accessed from prior GWAS. Genotype, diagnosis, and neuropathological data may be requested and upon approval of reasonable requests may be shared with individual investigators. Data requests can be completed through the Penn Neurodegenerative Data Sharing Committee webform: https://www.pennbindlab.com/data-sharing
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Manuscript and supplemental file updated
Data Availability
All summary statistic data was accessed from prior GWAS. Genotype, diagnosis, and neuropathological data may be requested and upon approval of reasonable requests may be shared with individual investigators. Data requests can be completed through the Penn Neurodegenerative Data Sharing Committee webform: https://www.pennbindlab.com/data-sharing